Mergers & Acquisitions ·
On July 16, 2026, Jasper Therapeutics, Inc. completed the acquisition of Kira Pharmaceuticals through a merger agreement
JSPRJasper Therapeutics, Inc.
On July 16, 2026, Jasper Therapeutics, Inc. completed the acquisition of Kira Pharmaceuticals through a merger agreement. The transaction involved the issuance of 5,195,009 shares of voting common stock and 4,644,977 shares of non-voting convertible preferred stock to Kira shareholders. Concurrently, Jasper completed a $132 million private placement (PIPE) involving the sale of approximately 4.7 million shares of preferred stock. The merger includes a contingent value right (CVR) agreement providing an aggregate $30 million milestone payment if the FDA issues a Priority Review Voucher for briquilimab by December 31, 2028. Jasper appointed Matthew Ros as Chief Operating Officer and Patrick Crutcher to the Board. Jasper Therapeutics is a biotechnology company developing immunologically-driven therapeutics.